Shanghai Henlius Biotech, Inc.
2696.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.58B
Close$
$-25.58
149.8% downside
Current Fair Value
149.8% downsideOvervalued by 149.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $27.58 Billion |
|---|---|
| Enterprise Value | $30.71 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.47 |
| Beta | 0.52 |
| Outstanding Shares | 544,857,075 |
Return
| Return on Equity | 19.11% |
|---|---|
| Return on Assets | 6.62% |
| Return on Invested Capital | 10.59% |
Valuation & Multiples
| P/E Ratio | 27.17 |
|---|---|
| PEG | 262.98 |
| Price to Sales | 3.95 |
| Price to Book Ratio | 6.43 |
| Enterprise Value to Revenue | 4.13 |
| Enterprise Value to EBIT | 34.55 |
| Enterprise Value to Net Income | 35 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.87 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
$0.50
Average shareholder expectationRevenue Estimate
$3.93 B
Average shareholder expectationNext Earnings Call
Expected Date
March 19, 2027
EPS Estimate
$0.98
Average shareholder expectationRevenue Estimate
$4.85 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shanghai Henlius Biotech, Inc.
4,082 employees
CEO: Jun Zhu Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial ...